The TOMATO study (TacrOlimus MetabolizAtion in kidney TransplantatiOn): impact of the concentration-dose ratio on death-censored graft survival.
Tacrolimus trough concentrations (mean/variability), as well as concentration-to-dose ratio (CDr), affect kidney-allograft outcomes. We investigated the link between the CDr and death-censored kidney-graft survival (DCGS). We performed a retrospective study on 1029 kidney transplant patients (2004-2016) with the following criteria: tacrolimus-based immunosuppression, >1-year graft survival, no initial use of everolimus, available anti-HLA antibody data. We analyzed the impact of the time-varying CDr on DCGS. Fast metabolizers were defined by a CDr<1.05. We also investigated the effect of an early (Month-3 to Month-6 post transplantation) CDr below 1.05. Cox survival analyses were performed, adjusting for potential confounders (tacrolimus trough, variability of tacrolimus trough, de novo DSA development, CYP3A5 genotype, pregraft sensitization, Month-3 GFR). Time-varying CDr was significantly associated with DCGS (HR 2.35, p<0.001) in a univariate model, on the full analysis set comprising 1029 patients. In the multivariate time-varying model, based on 666 patients with available CYP3A5 genotypes, the effect of the CDr remained significant (HR 2.26, p=0.015), even when GFR at month-3 < 30 ml/min/1,73m2 (HR 2.61, p=.011) dnDSA development (HR 4.09, p<0.001) and continued steroid prescription (HR=2.08, p=0.014) were taken into account (other covariates, including tacrolimus trough concentrations, were nonsignificant). In the same multivariate model, the effect of early CDr (median at M3 and M6) remained significantly associated with DCGS (HR=2.25, p=0.041). CDr is an independent and early predictor of DCGS. Identification of fast metabolizers could be a strategy to improve graft survival, e.g., by optimizing tacrolimus formulation. Mechanistic studies to understand the CDr effect are required.